ヒトマイクロバイオーム市場規模・予測、世界・地域シェア、動向、成長機会分析レポート：タイプ別、用途別、疾患タイプ別、地域別

ヒトマイクロバイオーム市場は、2023年の10億7,000万米ドルから2031年には48億4,000万米ドルに達すると予測され、2023年から2031年にかけてのCAGRは20.8%と推定されます。市場成長を促進する主な要因は、主要市場企業による多額の投資と政府の取り組みです。さらに、精密医療の出現が予測期間中に市場を押し上げる可能性が高いです。しかし、商業化時の課題が市場阻害要因の一つとなっています。

ヒトマイクロバイオーム産業の成長、革新、市場力学は、市場の主要企業による投資に大きく影響されます。大手企業は、マイクロバイオームに基づく新規プロバイオティクス、診断薬、治療法を生み出すための研究開発に多額の投資を行っています。こうした投資は技術革新を刺激し、新しい菌株、作用機序、医薬用途を特定します。臨床試験には多額の資金が投入されており、マイクロバイオームに基づく製品の有効性と安全性を実証するために不可欠です。マイクロバイオームマッピング技術のパイオニアであるカンヴァス・バイオサイエンシズは、2023年6月に1,200万米ドルのプレシリーズA資金調達を発表しました。同社が独自に開発したプラットフォーム技術は、マイクロバイオームに関連する疾病に対する医薬品開発を一変させる可能性を秘めており、今回の投資によってさらに開発が進むことになります。このようなパートナーシップは、リソースやノウハウ、技術的進歩の共有を容易にし、製品開発を加速させる。例えば、世界最大の飲食品会社ネスレとSFIトップクラスの研究センターであるAPCマイクロバイオーム・アイルランドとの新たな共同研究が2023年7月に発表されました。この共同研究は、ヒトマイクロバイオームのさまざまな側面に焦点を当て、人間の健康とウェルネスを向上させる新製品の開発を支援するものです。マイクロバイオーム解析に投資している企業は120社に上ると言われ、数多くの新興企業がこの分野に参入しています。フラッグシップ・パイオニアリング、セベンチュール・パートナーズ、バイオガイアが最も積極的な投資家です。このように、主要企業による投資の増加は、市場の成長を促進する可能性が高いです。

競合企業比較分析では、製品ポートフォリオ（製品満足度、製品特徴、入手可能性）、最近の市場動向（合併・買収、新製品発売・強化、投資・資金調達、受賞、合意、提携・協力、認知、拡大）、競合情勢のより良い意思決定と理解を助ける地域的プレゼンスに基づいて、ヒトマイクロバイオーム市場を評価・分類しています。本レポートでは、世界のヒトマイクロバイオーム市場における主要ベンダーの最近の重要な動向とイノベーションについて深く調査しています。主な市場企業は、 MaaT Pharma; Ferring Holdings SA; Finch Therapeutics Group Inc; AOBiome Therapeutics Inc.; Seres Therapeutics Inc; Merck & Co Inc; Yakult Honsha Co., Ltd; Rebiotix; Inc; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc.社です。

ヒトマイクロバイオーム市場は、製品タイプとソフトウェアサービスタイプに分けられます。製品セグメントは2023年にヒトマイクロバイオーム市場でより大きなシェアを占めており、2023年から2031年にかけてより高いCAGRを記録すると予測されています。ヒトマイクロバイオームには、人体内および人体上に存在するすべての微生物が含まれます。これらの微生物は疾病管理に利用できる可能性を秘めています。マイクロバイオーム製品は、重篤な症状の治療や治療の個別化に有望視されています。マイクロバイオータは、神経疾患、炎症性疾患、がんと関連しています。

市場は用途に基づき、治療、診断、研究に区分されます。2023年のヒトマイクロバイオーム市場では、治療薬分野が最大のシェアを占めています。腸内微生物の重要な代謝ポテンシャルとヒトの健康維持における役割は、ヒトの疾患に対処するための治療薬として活用する新たな可能性を伴って出現しています。近年、マイクロバイオームモジュレーターとしても知られるマイクロバイオームに基づく治療薬が急速に進歩しています。いくつかの有望な候補が臨床パイプラインを進んでいます。例えば、2023年4月、フェリング・ファーマシューティカルズのVOWSTは、経口摂取する初の糞便微生物製剤であり、18歳以上の患者におけるクロストリジオイデス・ディフィシル（C. difficile）感染症の再発予防を適応として承認されました。

ヒトマイクロバイオーム市場は、疾患タイプ別に肥満、糖尿病、自己免疫疾患、がん、消化管疾患、その他に区分されます。2023年のヒトマイクロバイオーム市場では、GIT障害分野が最大のシェアを占めています。

ヒトマイクロバイオーム市場で事業を展開する企業は、さまざまな有機的・無機的戦略を採用しています。有機的戦略には主に、製品上市と製品承認が含まれます。市場で見られる無機的な成長戦略は、買収、提携、パートナーシップです。これらの成長戦略により、市場参入企業は事業を拡大し、地理的プレゼンスを高めるとともに、市場全体の成長に貢献することができます。さらに、買収や提携などの戦略は、顧客基盤を強化し、製品ポートフォリオを拡大するのに役立っています。ヒトマイクロバイオーム市場の主要企業による重要な発展の一部を以下に示します。

2024年3月、MaaT Pharma社は欧州でCHRONOSと呼ばれるレトロスペクティブ多施設試験を開始すると発表しました。この試験の目的は、MaaT013やマイクロバイオーム介入を受けていない患者に対する3次治療の有効性データを提供することです。この試験は規制当局から要請されたものではなく、すでに資金が確保されているため、資金計画には影響しないです。

2021年7月、Seres Therapeutics, Inc.とNestle Health Science社は、再発性クロストリジオイデスディフィシル（CDI）感染症に対するSeres社の経口マイクロバイオーム治療薬SER-109を米国およびカナダで共同商業化するための商業化ライセンス契約を締結しました。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

• 主要な洞察

第3章 調査手法

• 2次調査
• 1次調査
  • 仮説の策定
  • マクロ経済要因分析
  • 基礎数値の開発
  • データの三角測量
  • 国レベルのデータ

第4章 ヒトマイクロバイオーム市場情勢

• PEST分析

第5章 ヒトマイクロバイオーム市場：主要市場力学

• ヒトマイクロバイオーム市場- 主要市場力学
• 市場促進要因
  • 主要市場企業による多額の投資
  • 政府の取り組み
• 市場抑制要因
  • 商業化時の課題
• 市場機会
  • 研究開発への積極投資
• 今後の動向
  • 精密医療の出現
• 促進要因と抑制要因の影響

第6章 ヒトマイクロバイオーム市場：世界市場分析

• ヒトマイクロバイオーム市場の収益、2021年～2031年
• ヒトマイクロバイオーム市場の予測分析

第7章 ヒトマイクロバイオーム市場分析- タイプ別

• 製品
• ソフトウェアとサービス

第8章 ヒトマイクロバイオーム市場分析-用途別

• 治療薬
• 診断薬
• 調査

第9章 ヒトマイクロバイオーム市場の分析-疾患タイプ別

• 肥満
• 糖尿病
• 自己免疫疾患
• がん
• 消化器
• その他

第10章 ヒトマイクロバイオーム市場- 地域別分析

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • アジア太平洋地域のその他諸国
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東とアフリカ
• 中南米
  • ブラジル
  • アルゼンチン
  • その他中南米

第11章 競合情勢

• ヒトマイクロバイオーム市場における成長戦略
• 有機的成長戦略
• 無機的成長戦略

第12章 企業プロファイル

• MaaT Pharma
• Ferring Holdings SA
• AOBiome Therapeutics Inc
• Finch Therapeutics Group Inc
• Seres Therapeutics Inc
• Merck & Co Inc
• Yakult Honsha Co., Ltd.
• Rebiotix, Inc.
• IFF Nutrition & Biosciences
• Synthetic Biologics, Inc.

第13章 付録

List Of Tables

• Table 1. Human Microbiome Market Segmentation
• Table 2. Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Table 3. Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million) - by Type
• Table 4. Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million) - by Product
• Table 5. Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million) - by Application
• Table 6. Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million) - by Disease Type
• Table 7. North America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 8. North America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 9. North America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 10. North America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 11. North America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Country
• Table 12. United States: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 13. United States: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 14. United States: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 15. United States: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 16. Canada: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 17. Canada: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 18. Canada: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 19. Canada: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 20. Mexico: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 21. Mexico: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 22. Mexico: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 23. Mexico: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 24. Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 25. Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 26. Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 27. Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 28. Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Country
• Table 29. United Kingdom: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 30. United Kingdom: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 31. United Kingdom: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 32. United Kingdom: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 33. Germany: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 34. Germany: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 35. Germany: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 36. Germany: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 37. France: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 38. France: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 39. France: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 40. France: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 41. Italy: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 42. Italy: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 43. Italy: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 44. Italy: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 45. ADULT OBESITY, 2030
• Table 46. CHILD OBESITY, 2030
• Table 47. Spain: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 48. Spain: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 49. Spain: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 50. Spain: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 51. Rest of Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 52. Rest of Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 53. Rest of Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 54. Rest of Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 55. Asia Pacific: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 56. Asia Pacific: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 57. Asia Pacific: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 58. Asia Pacific: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 59. Asia Pacific: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Country
• Table 60. China: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 61. China: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 62. China: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 63. China: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 64. Japan: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 65. Japan: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 66. Japan: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 67. Japan: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 68. India: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 69. India: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 70. India: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 71. India: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 72. Australia: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 73. Australia: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 74. Australia: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 75. Australia: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 76. South Korea: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 77. South Korea: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 78. South Korea: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 79. South Korea: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 80. Rest of APAC: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 81. Rest of APAC: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 82. Rest of APAC: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 83. Rest of APAC: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 84. Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 85. Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 86. Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 87. Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 88. Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Country
• Table 89. South Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 90. South Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 91. South Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 92. South Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 93. Saudi Arabia: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 94. Saudi Arabia: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 95. Saudi Arabia: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 96. Saudi Arabia: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 97. United Arab Emirates: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 98. United Arab Emirates: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 99. United Arab Emirates: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 100. United Arab Emirates: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 101. Rest of Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 102. Rest of Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 103. Rest of Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 104. Rest of Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 105. South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 106. South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 107. South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 108. South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 109. South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Country
• Table 110. Brazil: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 111. Brazil: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 112. Brazil: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 113. Brazil: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 114. Argentina: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 115. Argentina: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 116. Argentina: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 117. Argentina: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 118. Rest of South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Type
• Table 119. Rest of South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Product
• Table 120. Rest of South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Application
• Table 121. Rest of South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million) - by Disease Type
• Table 122. Recent Organic Growth Strategies in the Human Microbiome Market
• Table 123. Recent Inorganic Growth Strategies in the Human Microbiome Market
• Table 124. Glossary of Terms, Microelectrode Array in Vitro Market

List Of Figures

• Figure 1. Human Microbiome Market Segmentation, by Geography
• Figure 2. PEST Analysis
• Figure 3. Impact Analysis of Drivers and Restraints
• Figure 4. Human Microbiome Market Revenue (US$ Million), 2021-2031
• Figure 5. Human Microbiome Market Share (%) - by Type (2023 and 2031)
• Figure 6. Product: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 7. Software and Services: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 8. Human Microbiome Market Share (%) - by Application (2023 and 2031)
• Figure 9. Therapeutics: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 10. Diagnostics: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 11. Research: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 12. Human Microbiome Market Share (%) - by Disease Type (2023 and 2031)
• Figure 13. Obesity: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 14. Diabetes: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 15. Autoimmune Disorder: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 16. Cancer: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 17. GIT: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 18. Others: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• Figure 19. Human Microbiome Market Breakdown by Region, 2023 and 2031 (%)
• Figure 20. North America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 21. North America: Human Microbiome Market Breakdown, by Type (2023 and 2031)
• Figure 22. North America: Human Microbiome Market Breakdown, by Product (2023 and 2031)
• Figure 23. North America: Human Microbiome Market Breakdown, by Application (2023 and 2031)
• Figure 24. North America: Human Microbiome Market Breakdown, by Disease Type (2023 and 2031)
• Figure 25. North America: Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
• Figure 26. United States: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 27. Canada: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 28. Mexico: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 29. Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 30. Europe: Human Microbiome Market Breakdown, by Type (2023 and 2031)
• Figure 31. Europe: Human Microbiome Market Breakdown, by Product (2023 and 2031)
• Figure 32. Europe: Human Microbiome Market Breakdown, by Application (2023 and 2031)
• Figure 33. Europe: Human Microbiome Market Breakdown, by Disease Type (2023 and 2031)
• Figure 34. Europe: Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
• Figure 35. United Kingdom: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 36. Germany: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 37. France: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 38. Italy: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 39. Spain: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 40. Rest of Europe: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 41. Asia Pacific: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 42. Asia Pacific: Human Microbiome Market Breakdown, by Type (2023 and 2031)
• Figure 43. Asia Pacific: Human Microbiome Market Breakdown, by Product (2023 and 2031)
• Figure 44. Asia Pacific: Human Microbiome Market Breakdown, by Application (2023 and 2031)
• Figure 45. Asia Pacific: Human Microbiome Market Breakdown, by Disease Type (2023 and 2031)
• Figure 46. Asia Pacific: Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
• Figure 47. China: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 48. Japan: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 49. India: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 50. Australia: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 51. South Korea: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 52. Rest of APAC: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 53. Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 54. Middle East and Africa: Human Microbiome Market Breakdown, by Type (2023 and 2031)
• Figure 55. Middle East and Africa: Human Microbiome Market Breakdown, by Product (2023 and 2031)
• Figure 56. Middle East and Africa: Human Microbiome Market Breakdown, by Application (2023 and 2031)
• Figure 57. Middle East and Africa: Human Microbiome Market Breakdown, by Disease Type (2023 and 2031)
• Figure 58. Middle East and Africa: Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
• Figure 59. South Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 60. Saudi Arabia: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 61. United Arab Emirates: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 62. Rest of Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 63. South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 64. South and Central America: Human Microbiome Market Breakdown, by Type (2023 and 2031)
• Figure 65. South and Central America: Human Microbiome Market Breakdown, by Product (2023 and 2031)
• Figure 66. South and Central America: Human Microbiome Market Breakdown, by Application (2023 and 2031)
• Figure 67. South and Central America: Human Microbiome Market Breakdown, by Disease Type (2023 and 2031)
• Figure 68. South and Central America: Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
• Figure 69. Brazil: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 70. Argentina: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 71. Rest of South and Central America: Human Microbiome Market - Revenue and Forecast to 2031(US$ Million)
• Figure 72. Growth Strategies in the Human Microbiome Market

The human microbiome market is expected to reach US$ 4.84 billion by 2031 from US$ 1.07 billion in 2023; the market is estimated to register a CAGR of 20.8% during 2023-2031. Major factors driving the market growth significant investments by key market players and government initiatives. Further, the emergence of precision medicine is likely to boost the market during the forecast period. However, challenges during commercialization are among the market deterrents.

The human microbiome industry's growth, innovation, and market dynamics are greatly influenced by the investments made by major players in the market. Major players are engaged in making significant investments in research and development to create novel probiotics, diagnostics, and treatments based on the microbiome. These expenditures stimulate innovation, identifying new strains, modes of action, and medicinal uses. Clinical trials receive a large amount of funding, which is essential for demonstrating the effectiveness and safety of products based on the microbiome. A pioneer in microbiome mapping technology, Kanvas Biosciences, announced a US$ 12 million Pre-Series A funding round in June 2023. The company's proprietary platform technology, which has the potential to transform drug development for illnesses linked to the microbiome, will be further developed with the help of the investment. These partnerships make sharing resources, know-how, and technological advancements easier, speeding up product development. For instance, a new collaboration was announced between the world's largest food and beverage company, Nestle, and a top-tier SFI research center, APC Microbiome Ireland, in July 2023. The collaboration centers on different aspects of the human microbiome and helps develop new products to enhance human health and wellness. As many as 120 companies are reportedly investing in microbiome analysis, and numerous startups are entering this field. Flagship Pioneering, Seventure Partners, and BioGaia are the most active investors. Thus, increase in investments by key players is likely drive the growth of market.

The comparative company analysis evaluates and categorizes the human microbiome market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global human microbiome market. The key market players are MaaT Pharma; Ferring Holdings SA; Finch Therapeutics Group Inc; AOBiome Therapeutics Inc.; Seres Therapeutics Inc; Merck & Co Inc; Yakult Honsha Co., Ltd; Rebiotix; Inc; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc.

The human microbiome market, based on type, is segmented into product and software and services. The product segment held a larger share of the human microbiome market in 2023, and it is expected to register a higher CAGR during 2023-2031. The human microbiome includes all microorganisms in and on the human body. These microbes have potential for use in disease management. Microbiome products show promise in treating severe conditions and personalizing therapy. The microbiota has been linked to neurological diseases, inflammatory diseases, and cancer.

Based on application, the market is segmented into therapeutics, diagnostics, and research. The therapeutics segment accounted for the largest share of the human microbiome market in 2023. The significant metabolic potential of gut microbes and their role in maintaining human health is emerging, with new possibilities to utilize them as therapeutic agents for addressing human disorders. In recent years, microbiome-based therapeutics, also known as microbiome modulators, have made rapid advances. Several promising candidates have moved forward through the clinical pipeline. For instance, in April 2023, Ferring Pharmaceuticals' VOWST, the first fecal microbiota product taken orally, was approved for preventing recurrence of Clostridioides difficile (C. difficile) infection in patients 18 years and older, following antibiotic treatment for recurrent infection.

Based on disease type, the human microbiome market is segmented into obesity, diabetes, autoimmune disorders, cancer, GIT disorders, and others. The GIT disorders segment held the largest share of the human microbiome market in 2023.

Various organic and inorganic strategies are adopted by companies operating in the human microbiome market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the human microbiome market are listed below.

In March 2024, MaaT Pharma announced the launch of a retrospective multicenter trial called CHRONOS in Europe. Its objective is to provide the Company efficacy data for 3rd-line therapies for patients not receiving MaaT013 or any microbiome intervention. This study was not requested by regulatory authorities and does not impact cash projections as funding has already been secured.

In July 2021, Seres Therapeutics, Inc. and Nestle Health Science entered into commercialization license agreement to jointly commercialize SER-109, Seres' investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Human Microbiome Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis

5. Human Microbiome Market - Key Market Dynamics

• 5.1 Human Microbiome Market - Key Market Dynamics
• 5.2 Market Drivers
  • 5.2.1 Significant Investments by Key Market Players
  • 5.2.2 Government Initiatives
• 5.3 Market Restraints
  • 5.3.1 Challenges During Commercialization
• 5.4 Market Opportunities
  • 5.4.1 Robust Investment in Research and Development
• 5.5 Future Trends
  • 5.5.1 Emergence of Precision Medicine
• 5.6 Impact of Drivers and Restraints:

6. Human Microbiome Market - Global Market Analysis

• 6.1 Human Microbiome Market Revenue (US$ Million), 2021-2031
• 6.2 Human Microbiome Market Forecast Analysis

7. Human Microbiome Market Analysis - by Type

• 7.1 Product
  • 7.1.1 Overview
  • 7.1.2 Product: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• 7.2 Software and Services
  • 7.2.1 Overview
  • 7.2.2 Software and Services: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)

8. Human Microbiome Market Analysis - by Application

• 8.1 Therapeutics
  • 8.1.1 Overview
  • 8.1.2 Therapeutics: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• 8.2 Diagnostics
  • 8.2.1 Overview
  • 8.2.2 Diagnostics: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• 8.3 Research
  • 8.3.1 Overview
  • 8.3.2 Research: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)

9. Human Microbiome Market Analysis - by Disease Type

• 9.1 Obesity
  • 9.1.1 Overview
  • 9.1.2 Obesity: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• 9.2 Diabetes
  • 9.2.1 Overview
  • 9.2.2 Diabetes: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• 9.3 Autoimmune Disorder
  • 9.3.1 Overview
  • 9.3.2 Autoimmune Disorder: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• 9.4 Cancer
  • 9.4.1 Overview
  • 9.4.2 Cancer: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• 9.5 GIT
  • 9.5.1 Overview
  • 9.5.2 GIT: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
• 9.6 Others
  • 9.6.1 Overview
  • 9.6.2 Others: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)

10. Human Microbiome Market - Geographical Analysis

• 10.1 Overview
• 10.2 North America
  • 10.2.1 North America Human Microbiome Market Overview
  • 10.2.2 North America: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2.3 North America: Human Microbiome Market Breakdown, by Type
    • 10.2.3.1 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Type
  • 10.2.4 North America: Human Microbiome Market Breakdown, by Product
    • 10.2.4.1 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Product
  • 10.2.5 North America: Human Microbiome Market Breakdown, by Application
    • 10.2.5.1 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Application
  • 10.2.6 North America: Human Microbiome Market Breakdown, by Disease Type
    • 10.2.6.1 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Disease Type
  • 10.2.7 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Country
    • 10.2.7.1 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Country
    • 10.2.7.2 United States: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.2.7.2.1 United States: Human Microbiome Market Breakdown, by Type
      • 10.2.7.2.2 United States: Human Microbiome Market Breakdown, by Product
      • 10.2.7.2.3 United States: Human Microbiome Market Breakdown, by Application
      • 10.2.7.2.4 United States: Human Microbiome Market Breakdown, by Disease Type
    • 10.2.7.3 Canada: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.2.7.3.1 Canada: Human Microbiome Market Breakdown, by Type
      • 10.2.7.3.2 Canada: Human Microbiome Market Breakdown, by Product
      • 10.2.7.3.3 Canada: Human Microbiome Market Breakdown, by Application
      • 10.2.7.3.4 Canada: Human Microbiome Market Breakdown, by Disease Type
    • 10.2.7.4 Mexico: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.2.7.4.1 Mexico: Human Microbiome Market Breakdown, by Type
      • 10.2.7.4.2 Mexico: Human Microbiome Market Breakdown, by Product
      • 10.2.7.4.3 Mexico: Human Microbiome Market Breakdown, by Application
      • 10.2.7.4.4 Mexico: Human Microbiome Market Breakdown, by Disease Type
• 10.3 Europe
  • 10.3.1 Europe Human Microbiome Market Overview
  • 10.3.2 Europe: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3.3 Europe: Human Microbiome Market Breakdown, by Type
    • 10.3.3.1 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Type
  • 10.3.4 Europe: Human Microbiome Market Breakdown, by Product
    • 10.3.4.1 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Product
  • 10.3.5 Europe: Human Microbiome Market Breakdown, by Application
    • 10.3.5.1 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Application
  • 10.3.6 Europe: Human Microbiome Market Breakdown, by Disease Type
    • 10.3.6.1 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Disease Type
  • 10.3.7 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Country
    • 10.3.7.1 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Country
    • 10.3.7.2 United Kingdom: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.3.7.2.1 United Kingdom: Human Microbiome Market Breakdown, by Type
      • 10.3.7.2.2 United Kingdom: Human Microbiome Market Breakdown, by Product
      • 10.3.7.2.3 United Kingdom: Human Microbiome Market Breakdown, by Application
      • 10.3.7.2.4 United Kingdom: Human Microbiome Market Breakdown, by Disease Type
    • 10.3.7.3 Germany: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.3.7.3.1 Germany: Human Microbiome Market Breakdown, by Type
      • 10.3.7.3.2 Germany: Human Microbiome Market Breakdown, by Product
      • 10.3.7.3.3 Germany: Human Microbiome Market Breakdown, by Application
      • 10.3.7.3.4 Germany: Human Microbiome Market Breakdown, by Disease Type
    • 10.3.7.4 France: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.3.7.4.1 France: Human Microbiome Market Breakdown, by Type
      • 10.3.7.4.2 France: Human Microbiome Market Breakdown, by Product
      • 10.3.7.4.3 France: Human Microbiome Market Breakdown, by Application
      • 10.3.7.4.4 France: Human Microbiome Market Breakdown, by Disease Type
    • 10.3.7.5 Italy: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.3.7.5.1 Italy: Human Microbiome Market Breakdown, by Type
      • 10.3.7.5.2 Italy: Human Microbiome Market Breakdown, by Product
      • 10.3.7.5.3 Italy: Human Microbiome Market Breakdown, by Application
      • 10.3.7.5.4 Italy: Human Microbiome Market Breakdown, by Disease Type
    • 10.3.7.6 Spain: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.3.7.6.1 Spain: Human Microbiome Market Breakdown, by Type
      • 10.3.7.6.2 Spain: Human Microbiome Market Breakdown, by Product
      • 10.3.7.6.3 Spain: Human Microbiome Market Breakdown, by Application
      • 10.3.7.6.4 Spain: Human Microbiome Market Breakdown, by Disease Type
    • 10.3.7.7 Rest of Europe: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.3.7.7.1 Rest of Europe: Human Microbiome Market Breakdown, by Type
      • 10.3.7.7.2 Rest of Europe: Human Microbiome Market Breakdown, by Product
      • 10.3.7.7.3 Rest of Europe: Human Microbiome Market Breakdown, by Application
      • 10.3.7.7.4 Rest of Europe: Human Microbiome Market Breakdown, by Disease Type
• 10.4 Asia Pacific
  • 10.4.1 Asia Pacific Human Microbiome Market Overview
  • 10.4.2 Asia Pacific: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4.3 Asia Pacific: Human Microbiome Market Breakdown, by Type
    • 10.4.3.1 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Type
  • 10.4.4 Asia Pacific: Human Microbiome Market Breakdown, by Product
    • 10.4.4.1 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Product
  • 10.4.5 Asia Pacific: Human Microbiome Market Breakdown, by Application
    • 10.4.5.1 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Application
  • 10.4.6 Asia Pacific: Human Microbiome Market Breakdown, by Disease Type
    • 10.4.6.1 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Disease Type
  • 10.4.7 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Country
    • 10.4.7.1 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Country
    • 10.4.7.2 China: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.4.7.2.1 China: Human Microbiome Market Breakdown, by Type
      • 10.4.7.2.2 China: Human Microbiome Market Breakdown, by Product
      • 10.4.7.2.3 China: Human Microbiome Market Breakdown, by Application
      • 10.4.7.2.4 China: Human Microbiome Market Breakdown, by Disease Type
    • 10.4.7.3 Japan: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.4.7.3.1 Japan: Human Microbiome Market Breakdown, by Type
      • 10.4.7.3.2 Japan: Human Microbiome Market Breakdown, by Product
      • 10.4.7.3.3 Japan: Human Microbiome Market Breakdown, by Application
      • 10.4.7.3.4 Japan: Human Microbiome Market Breakdown, by Disease Type
    • 10.4.7.4 India: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.4.7.4.1 India: Human Microbiome Market Breakdown, by Type
      • 10.4.7.4.2 India: Human Microbiome Market Breakdown, by Product
      • 10.4.7.4.3 India: Human Microbiome Market Breakdown, by Application
      • 10.4.7.4.4 India: Human Microbiome Market Breakdown, by Disease Type
    • 10.4.7.5 Australia: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.4.7.5.1 Australia: Human Microbiome Market Breakdown, by Type
      • 10.4.7.5.2 Australia: Human Microbiome Market Breakdown, by Product
      • 10.4.7.5.3 Australia: Human Microbiome Market Breakdown, by Application
      • 10.4.7.5.4 Australia: Human Microbiome Market Breakdown, by Disease Type
    • 10.4.7.6 South Korea: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.4.7.6.1 South Korea: Human Microbiome Market Breakdown, by Type
      • 10.4.7.6.2 South Korea: Human Microbiome Market Breakdown, by Product
      • 10.4.7.6.3 South Korea: Human Microbiome Market Breakdown, by Application
      • 10.4.7.6.4 South Korea: Human Microbiome Market Breakdown, by Disease Type
    • 10.4.7.7 Rest of APAC: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.4.7.7.1 Rest of APAC: Human Microbiome Market Breakdown, by Type
      • 10.4.7.7.2 Rest of APAC: Human Microbiome Market Breakdown, by Product
      • 10.4.7.7.3 Rest of APAC: Human Microbiome Market Breakdown, by Application
      • 10.4.7.7.4 Rest of APAC: Human Microbiome Market Breakdown, by Disease Type
• 10.5 Middle East and Africa
  • 10.5.1 Middle East and Africa Human Microbiome Market Overview
  • 10.5.2 Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.5.3 Middle East and Africa: Human Microbiome Market Breakdown, by Type
    • 10.5.3.1 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Type
  • 10.5.4 Middle East and Africa: Human Microbiome Market Breakdown, by Product
    • 10.5.4.1 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Product
  • 10.5.5 Middle East and Africa: Human Microbiome Market Breakdown, by Application
    • 10.5.5.1 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Application
  • 10.5.6 Middle East and Africa: Human Microbiome Market Breakdown, by Disease Type
    • 10.5.6.1 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Disease Type
  • 10.5.7 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Country
    • 10.5.7.1 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Country
    • 10.5.7.2 South Africa: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.5.7.2.1 South Africa: Human Microbiome Market Breakdown, by Type
      • 10.5.7.2.2 South Africa: Human Microbiome Market Breakdown, by Product
      • 10.5.7.2.3 South Africa: Human Microbiome Market Breakdown, by Application
      • 10.5.7.2.4 South Africa: Human Microbiome Market Breakdown, by Disease Type
    • 10.5.7.3 Saudi Arabia: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.5.7.3.1 Saudi Arabia: Human Microbiome Market Breakdown, by Type
      • 10.5.7.3.2 Saudi Arabia: Human Microbiome Market Breakdown, by Product
      • 10.5.7.3.3 Saudi Arabia: Human Microbiome Market Breakdown, by Application
      • 10.5.7.3.4 Saudi Arabia: Human Microbiome Market Breakdown, by Disease Type
    • 10.5.7.4 United Arab Emirates: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.5.7.4.1 United Arab Emirates: Human Microbiome Market Breakdown, by Type
      • 10.5.7.4.2 United Arab Emirates: Human Microbiome Market Breakdown, by Product
      • 10.5.7.4.3 United Arab Emirates: Human Microbiome Market Breakdown, by Application
      • 10.5.7.4.4 United Arab Emirates: Human Microbiome Market Breakdown, by Disease Type
    • 10.5.7.5 Rest of Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.5.7.5.1 Rest of Middle East and Africa: Human Microbiome Market Breakdown, by Type
      • 10.5.7.5.2 Rest of Middle East and Africa: Human Microbiome Market Breakdown, by Product
      • 10.5.7.5.3 Rest of Middle East and Africa: Human Microbiome Market Breakdown, by Application
      • 10.5.7.5.4 Rest of Middle East and Africa: Human Microbiome Market Breakdown, by Disease Type
• 10.6 South and Central America
  • 10.6.1 South and Central America Human Microbiome Market Overview
  • 10.6.2 South and Central America: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.6.3 South and Central America: Human Microbiome Market Breakdown, by Type
    • 10.6.3.1 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Type
  • 10.6.4 South and Central America: Human Microbiome Market Breakdown, by Product
    • 10.6.4.1 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Product
  • 10.6.5 South and Central America: Human Microbiome Market Breakdown, by Application
    • 10.6.5.1 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Application
  • 10.6.6 South and Central America: Human Microbiome Market Breakdown, by Disease Type
    • 10.6.6.1 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Disease Type
  • 10.6.7 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Country
    • 10.6.7.1 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Country
    • 10.6.7.2 Brazil: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.6.7.2.1 Brazil: Human Microbiome Market Breakdown, by Type
      • 10.6.7.2.2 Brazil: Human Microbiome Market Breakdown, by Product
      • 10.6.7.2.3 Brazil: Human Microbiome Market Breakdown, by Application
      • 10.6.7.2.4 Brazil: Human Microbiome Market Breakdown, by Disease Type
    • 10.6.7.3 Argentina: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.6.7.3.1 Argentina: Human Microbiome Market Breakdown, by Type
      • 10.6.7.3.2 Argentina: Human Microbiome Market Breakdown, by Product
      • 10.6.7.3.3 Argentina: Human Microbiome Market Breakdown, by Application
      • 10.6.7.3.4 Argentina: Human Microbiome Market Breakdown, by Disease Type
    • 10.6.7.4 Rest of South and Central America: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.6.7.4.1 Rest of South and Central America: Human Microbiome Market Breakdown, by Type
      • 10.6.7.4.2 Rest of South and Central America: Human Microbiome Market Breakdown, by Product
      • 10.6.7.4.3 Rest of South and Central America: Human Microbiome Market Breakdown, by Application
      • 10.6.7.4.4 Rest of South and Central America: Human Microbiome Market Breakdown, by Disease Type

11. Competitive Landscape

• 11.1 Overview
• 11.2 Growth Strategies in the Human Microbiome Market
• 11.3 Organic Growth Strategies
  • 11.3.1 Overview
• 11.4 Inorganic Growth Strategies
  • 11.4.1 Overview

12. Company Profiles

• 12.1 MaaT Pharma
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Ferring Holdings SA
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 AOBiome Therapeutics Inc
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 Finch Therapeutics Group Inc
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Financial Overview
  • 12.4.4 SWOT Analysis
  • 12.4.5 Key Developments
• 12.5 Seres Therapeutics Inc
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 Merck & Co Inc
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
• 12.7 Yakult Honsha Co., Ltd.
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
• 12.8 Rebiotix, Inc.
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
• 12.9 IFF Nutrition & Biosciences
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments
• 12.10 Synthetic Biologics, Inc.
  • 12.10.1 Key Facts
  • 12.10.2 Business Description
  • 12.10.3 Products and Services
  • 12.10.4 Financial Overview
  • 12.10.5 SWOT Analysis
  • 12.10.6 Key Developments

13. Appendix

• 13.1 Glossary of Terms
• 13.2 About The Insight Partners